Leukaemia Care Webinar 8th April - a bit more ... - CLL Support

CLL Support

22,532 members38,709 posts

Leukaemia Care Webinar 8th April - a bit more information

Jm954 profile image
Jm954Administrator
17 Replies

Professor Dr Chris Fegan talked about CLL and COVID19 and answered previously submitted questions.

Following on from AdrianUK's post ( healthunlocked.com/cllsuppo... ) this is a second report.

His main message was that ALL CLL and SLL patients should be shielded, even stage A, watch and wait patients because our immune systems are not normal. He emphasised just how very infectious this virus is and likened it to the infection rate of Ebola. However, CLL patients are no more likely to catch this virus than any other person.

Within the home, if one person is going out then you should try to isolate from the person who is leaving the home but if your whole household is staying indoors then after 10-14 days you do not need to isolate from each other.

Important to consider how the virus can get into your home and the main routes could be your shopping and the post. He reiterated the important advice to wash your hands regularly and keep them away from your face to stay safe.

Can friends come to your gate and talk - yes! Just maintain the 2m safe distance.

Should you go out to get your prescription - No, try to get someone else to do it.

He has some interesting information regarding their practice for patients that need to start treatment. If the treatment can safely be delayed then delay it if you and your Dr agree. However, if starting treatment is urgent then giving something that does not have such a bad impact on the immune system is better. Chemo knocks out not just the immune system but also neutrophils which deepens the immunosuppression. That might be chlorambucil or, as AdrianUK mentioned yesterday, there is a patient access scheme for Acalabrutinib which is a good alternative for many patients. Venetoclax has the disadvantage of having a bigger negative impact on neutrophils and the need for close monitoring at the start/ramp up phase so unlikely to start on this in the current situation.

Interestingly he also said that for those patients on Ibruitnib/Acalabrutinib then, theoretically, the treatment could be protective from the cytokine storm that causes the damage in COVID patients.

For some patients a pause in treatment is reasonable and a better option than continuing with chemo-immunotherapy.

For patients in clinical trials, they are giving them 6 month appointments and couriering out their medication. There is no risk to the drug supply. Blood tests are not easy to arrange with GPs so ask your consultant what they recommend. BUT do not wait until a day or two before you need any advice as most of the haematology teams are being redeployed to the COVID front line and it could take a while to get a response. Email might be better than telephoning.

Regarding ivig - they have been giving their patients 3 months of antibiotics to see them through this period. Going to the day unit for ivig may not be possible and too great a risk to all concerned. Those with sc ivig should make sure they clean it well when it arrives.

The biggest threat to any CLL patient's life is a chest infection, at any time, not just now with COVID. Only 15-20% of CLL patients make antibodies to the flu vaccination so vaccination will not necessarily be the answer for most of us. Herd immunity will be very important.

In his role as R+D Director he said they had opened 8 COVID studies in the last 3 weeks comprising three strands - 1. anti virals use, 2 stopping the immune systems inflammatory response and 3. use of oxygen pressure and positioning patients on their front.

Finally, he said that if you need to go to hospital do not worry if the staff do not have masks, goggles and it seems business as usual. That is a good sign that you are in a non COVID area of the hospital.

Remember, stay home, stay safe

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .
Read more about...
17 Replies
Newdawn profile image
NewdawnAdministrator

That’s incredibly useful. Thanks Jackie.

Newdawn

Beattiem-UK profile image
Beattiem-UK

Thank you Jackie. Clear and informative. 😊

JigFettler profile image
JigFettlerVolunteer

Thanks Jackie - I found Chris Fegan informative and helpful - as always.

Jig

HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin

Jackie thank your for your review to help patients understand the key points given by Prof Fegan yesterday. Thank you to everyone who joined us.

Everyone can now watch the video of the webinar below if they cannot remember all or wish to see as registration was filled

youtube.com/watch?v=-kuS2vJ...

Ernest2 profile image
Ernest2 in reply to HAIRBEAR_UK

Hi Nick,

Can you please pass all our thanks to the Leukaemia Care team and Prof Chris Vegan for the presentation.

Lots of clear thinking and common sense.

Best wishes,

Ernest

Wroxham profile image
Wroxham in reply to HAIRBEAR_UK

Thank to Nick, Charlotte and Professor Chris Fegan. Very successful webinar.

Sue

Jm954 profile image
Jm954Administrator

Thanks Nick ! :)

Jackie

Peggy4 profile image
Peggy4

Great to watch. Many thanks Nick. I found it helpful to hear advice specifically aimed at CLL patients. The take away points for the W&W low grade patients like myself were endorsing the need for even us to shield and the fact that although we are no more likely to get it than anyone else, the outcome could be unthinkable.

Many thanks to all concerned in the making of this and Prof Fegan for giving up his time.

Peggy 😀

Wroxham profile image
Wroxham

Brilliant summary Jackie. Many thanks.

Sue.

Justasheet1 profile image
Justasheet1

Jackie,

Where did the doc say this?

“Interestingly he also said that for those patients on Ibruitnib/Acalabrutinib then, theoretically, the treatment could be protective from the cytokine storm that causes the damage in COVID patients.”

I didn’t hear that in the video.

Jeff

Newdawn profile image
NewdawnAdministrator in reply to Justasheet1

Jackie will need to answer that as I didn’t hear the video but Dr. Koffman certainly mentioned the same possibility in a post on here the other day when he said;

‘Ibrutinib may be actually mildly beneficial for CLL patients with COVID-19. Modulates the immune response, as it does with CAR-T. It is being studied.’

It’s a theory that clearly has some traction.

Jeff

Justasheet1 profile image
Justasheet1 in reply to Newdawn

Newdawn,

I’m on ibrutinib so I’ll take any good news there is.

Now if I could only catch malaria, I could get the chloroquine. 😂

Just kidding.

Jeff

Wroxham profile image
Wroxham in reply to Justasheet1

It was deffo said in video Jeff.

Sue

Wroxham profile image
Wroxham in reply to Wroxham

They believe it helps to stop the cykotine storm. Trials are looking at this also .

Sue

Justasheet1 profile image
Justasheet1 in reply to Wroxham

Sue,

I believe you and Jackie. I just could never find it there. I did a post on Actemra. It’s an IL-6 blocker for rheumatoid arthritis that stops the cytokine storm. It’s actually in China’s protocol for treatment. It’s getting people off the vents in many cases. It’s in a phase 3 clinical trial for this in the states.

I have much hope that this virus will pass. There’s too many geniuses put on earth by God mixed in with the idiots not to have hope.

Jeff

Newdawn profile image
NewdawnAdministrator in reply to Justasheet1

Hope you’re right Jeff or we are all in this for the long haul! 🥴

Newdawn

Psmithuk profile image
Psmithuk

Thank you for this, good to hear the follow up. Professor Fegan is so good - all straightforward stuff that we can all understand.

Cx

You may also like...

COVID-19 and leukaemia - Leukaemia Care Webinar

regarding COVID-19 and leukaemia, it was mentioned that there was a recruiting study for Covid...

Leukaemia Care Webinar: Navigating changes as shielding pauses

webinar with leading haematologists from different specialisms to aid patients and their families...

Leukaemia Care Updated Patient Information - Richter's Syndrome in Chronic Lymphocytic Leukaemia

samples of patients with RT, this research has revealed early seeding of Richter transformation in...

Acalabrutinib versus Covid19?

suggest that CLL patients in clinical trials prescribed Acalabrutinib who contract covid 19 are...

Don't forget your flu jab.

Check other vaccinations are up-to-date. CLL patients are immune compromised and should not...